Tucaresol and valerosol have shown to decrease the sickling of RBCs (in vitro) and the incidence of hemolysis in sickle cell disease without reducing oxygen supply to different tissues by increasing the affinity between Hb and oxygen by 20%-30% [1,6]. The gene discussed is GSTM1; the disease is sickle cell disease.